Skip to main content

Table 1 Summary table of the meta-analysis

From: The D-dimer level predicts the prognosis in patients with lung cancer: a systematic review and meta-analysis

Auther(year) Country Samplesize(N) (F/M) Cutoff value Age (range) Follow-up (median) Detection method Outcomes Quality assessment
Buccheri et al. [17] Italy 286(31/255) 0.5 g/mL 61 (32–87) 34 months Latex assay OS 7
Taguchi et al. [18] Japan 70 150 ng/ml 65 (20–83) 15 months ELISA OS 5
Ferrigno et al. [19] Italy 343(31/304) 0.5 ug/ml 68 (39–86) - Immunoturbidimetry OS 8
Pavey et al. [20] Australia 166(38/128) 32.99 ng/ml 64 (30–86) 270 days ELISA OS 8
Buccheri et al. [21] Italy 826(99/727) 0.5 ug/ml 67 (35–89) 34 weeks Immunoturbidimetry OS 8
Altiay et al. [23] Turkey 78(5/73) 0.65 ug/ml 61 (37–82) 264 days ELISA OS 8
Komurcuoglu et al. [24] Turkey 100(14/86) 1250 ng/dl 67 - ELISA OS 6
Masago et al. [25] Japan 99(28/71) 0.6 ng/ml 72(35–88) 0–800 days ELISA OS 8
Ay et al. [26] Austria 182 0.84 g/mL 62 (52–68) 731 days Latex assay OS 7
Tas et al. [2] Turkey 110(10/100) 360 IU/ml 59(35–80) 20.3 weeks Microparticle Enzyme Immunoassay OS 7
Zhang et al. [27] China 232 (83/149) 0.3 ug/ml 61(30–86) 47.0 months Immunoturbidimetry OS 6
Fukumoto et al. [28] Japan 237(85/152) 0.50 lg/ml 69(31–85) 51.6 months - OS 7
Ursavaş et al. [29] Turkey 65 (10/55) 375 μg/L 60 0–1,000 days Latex assay OS  
Ge et al. [30] China 82(27/55) - 64 (44–72) - Immunoturbidimetry OS/PFS 8
Inal et al. [9] Turkey 72(16/56) 1900 ng/mL - 574.14 days ELISA OS 8
Wang et al. [31] China 1929(604/1325) 0.5 μg/mL - 18.0 months Immunoturbidimetry OS/PFS 7
Chen et al. [22] China 393(71/322) 0.5 ug/ml 57(49–65) 12 months Immunoturbidimetry OS/PFS 6
Zhu et al. [32] China 74(17/57) 0.55 ug/L 57(42–80) 11.5 months Immunoturbidimetry OS/PFS 8
Jiang [33] China 107(23/84) 0.55 mg/L 63.0(58.5,68.0) 9 months Immunoturbidimetry OS 8
Sun [18] China 272(109/163) 0.55 mg/L 65 - - OS 6
Zhang et al. [34] China 160(31/129) 500 ng/ml 59 (23–83) - Immunoturbidimetry PFS 8
Fan et al. [35] China 82(15/67) 0.55 mg/L 60(28–82) 0–50 months Immunoturbidimetry PFS/OS 8
Hou et al. [36] China 395(170/225) 0.20 mg/L 64(56–69) 13.2 months Immunoturbidimetry OS 6
Liang et al. [37] China 456(138/318) 500 ng/ml 61(35–81) 42 months Immunoturbidimetry OS 8
Shiina et al. [38] Japan 235(89/146) 1.0 μg/ml 70 0–3 years - OS 8
Chen et al. [15] China 233(70/1630) 500 mg/ml 67 0–60 months ELISA OS 7
Liu et al. [16] China 651(216/435) 0.5 mg/L 60 0–80 months Immunoturbidimetry OS 7
Moik et al. [39] Russia 277(103/174) 1 mg/dl 61(56–67) 24 months Latex assay OS/PFS 8
Auther(year) Treatment Histology type Disease stage (T0/T1/T2/T3/T4)
Chemotherapy (alone/combination) Radiotherapy Chemo-radiation Surgery No anticancer treatment or supportive care
Buccheri et al. [17] - -   - - E/S/A/L/U 112/37/67/18/52 I/II/III/IV 42/31/119/94
Taguchi et al. [18] 50 20 0 NSCLC 49; SCLC 21 -   
Ferrigno et al. [19] 175 8 - 66 26% E/A/S/L/U 125/80/34/16/88 I/II/III/IV 69/26/124/121
Pavey et al. [20] - - - - - NSCLC 166(A/E/L/O 68/76/13/9) -
Buccheri et al. [21]       E/S/A/L/U 296/93/210/48/179 I/II/III/IV /149/57/310/305
Altiay et al. [23] 74 57   - 4 NSCLC 60; SCLC 18 III/IV 35/43
Komurcuoglu et al. [24] - -   - - NSCLC 87; SCLC 13 II/III/IV 15/50/35
Masago et al. [25] 67 2 8 - 22 A/E/N 68/18/13 III/IV42/57
Ay et al. [26] - - - - - - -
Tas et al. [2]       E/A/U/S 26/30/28/16  
Zhang et al. [27] - - - 232 - E/A 111/121 I-II/III 173/59
Fukumoto et al. [28] - - - 237 - E/A/L/O 51/162/7/17 -
Ursavaş et al. [29] - - - - - E/A/S/U 32/11/17/5 I/II/III/IV 20/5/16/32
Ge et al. [30] 82 - - - - N-SCC/SCC 53/29 IIIB/IV 10/72
Inal et al. [9] 72 - - - - E/A/N/S 19/14/24/15 III/IV 33/22
Wang et al. [31] - - - - - A/O 1046/885 IV1929
Chen et al. [22] 126 - 267 - - SCLC 393 -
Zhu et al. [32] 74 - - - - SCLC 74 -
Jiang [33] 25 - 82 - - SCLC 107 -
Sun [18] 177 - - - - N-SCLC 272 IV 272
Zhang et al. [34] 160 - - - - SCLC 160 LD/ED 38/122
Fan et al. [35] 27 - 51 - - SCLC 82 I + II + IIIa/IIIb + IV 19/63
Hou et al. [36] - - - 395 - NSCLC(E/A/O) 53/329/13 I-II/III 341/54
Liang et al. [37] - - - 456 - NSCLC 61 I/II/III 170/101/185
Shiina et al. [38] 46 2 9 235 - Adenocarcinoma/Squamous cell carcinoma/LCNEC/Large cell carcinoma/Pleomorphic carcinoma/Carcinoid 186/55/2/2/2/2 A/E/L/L/P/C 186/55/2/2/2/2 -
Chen et al. [15] - - - - - E/A/O 55/124/54 III/IV 110/123
Liu et al. [16] 492 70 89 E/A/O 126/504/21 III/IV98/553   
Moik et al. yy[39] 277 277 - 277 - NSCLC/SCLC 231/46 I/II/III/IV 1/4/76/196
  1. S:SCLC/small cell lung cancer;N:N-SCLC/non-small cell lung cancer;E:Epidermoid/Squamous cell carcinomas
  2. A: Adenocarcinoma;U: unclassified;L: Large cell carcinoma;O: others; LCNEC: large cell neuroendocrine carcinoma;'-': not mentioned